1 Evertrust Plaza
Jersey City, NJ 07302-6548
201 884 5485
Full-time employees: 36
|Mr. David Gonzalez Angulo M.D.||CEO, Pres & Director||631.69k||N/A||1965|
|Mr. Scott Sukenick J.D.||Chief Legal Officer & Corp. Sec.||542.05k||N/A||1978|
|Mr. Ivor Macleod CPA, M.B.A.||Chief Financial Officer||N/A||N/A||1961|
|Debbie Etchison||Exec. Director of Communications||N/A||N/A||N/A|
|Ms. Daniella Gigante||VP of HR||N/A||N/A||N/A|
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
SCYNEXIS, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.